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A defect in the coupling of the D1 receptor (D1R) to its G
protein/effector complex in renal proximal tubules plays a
role in the pathogenesis of spontaneous hypertension. As
there is no mutation of the D1R gene in the spontaneously
hypertensive rat (SHR), we tested the hypothesis that the
coupling defect is associated with constitutive
desensitization/phosphorylation of the D1R. The following
experiments were performed: (1) Cell culture and membrane
preparations from rat kidneys and immortalized rat renal
proximal tubule cells (RPTCs); (2) immunoprecipitation and
immunoblotting; (3) cyclic adenosine 30,50 monophosphate
and adenylyl cyclase assays; (4) immunofluorescence and
confocal microscopy; (5) biotinylation of cell surface
proteins; and (6) in vitro enzyme dephosphorylation. Basal
serine-phosphorylated D1Rs in renal proximal tubules, brush
border membranes, and membranes from immortalized
RPTCs were greater in SHRs (21.071.5 density units, DU) than
in normotensive rats (7.472.9 DU). The increased basal
serine phosphorylation of D1Rs in SHRs was accompanied by
decreased expression of D1R at the cell surface, and
decreased ability of a D1-like receptor agonist (fenoldopam)
to stimulate cyclic adenosine 30,50 monophosphate (cAMP)
production. Increasing protein phosphatase 2A activity with
protamine enhanced the ability of fenoldopam to stimulate
cAMP accumulation (1774%) and alter D1R cell surface
expression in intact cells from SHRs. Alkaline phosphatase
treatment of RPTC membranes decreased D1R
phosphorylation and enhanced fenoldopam stimulation of
adenylyl cyclase activity (2676%) in SHRs. Uncoupling of the
D1R from its G protein/effector complex in renal proximal
tubules in SHRs is caused, in part, by increased D1R serine
phosphorylation.
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Dopamine receptors in the central nervous system and
peripheral tissues have been implicated in the regulation of
blood pressure.1,2 Dopamine exerts its action via two families
of dopamine receptors that belong to the superfamily of G
protein-coupled receptors (GPCR). The D1-like receptor
family (D1A and D1B in rodents, D1 and D5 in humans) is
linked to stimulation of adenylyl cyclase, via the stimulatory
G protein, GaS. The D2-like receptor family (D2, D3, and D4)
is linked to inhibition of adenylyl cyclase, via the inhibitory
G proteins, Gai and GO. There are remarkable parallels in
the abnormal dopamine signaling, via D1-like receptors, in
rodent models of genetic hypertension (e.g., spontaneously
hypertensive rat (SHR)) and human essential hypertension.
Disruption of either one of the D1-like receptors (D1 or D5)
in mice leads to the development of hypertension.3,4 D1-like
receptor inhibition of NHE3, Naþ /HCO3
, Cl/HCO3
, and
Naþ /KþATPase activities in the renal proximal tubule and
medullary thick ascending limb of Henle is impaired in the
SHR and Dahl salt-sensitive rat.1,2,5–7 The impaired D1-like
receptor inhibitory effect on renal sodium transport in
hypertension has been shown to be caused, in part, by
impaired production of cytoplasmic second messengers.1,2,5–7
Despite the impairment of D1-like receptors to exert their
agonist effects in hypertension, there are no mutations in the
coding region of the D1R or D5R in patients with essential
hypertension or in genetically hypertensive rats.8 Instead,
in hypertension, the D1R in the renal proximal tubule
and medullary thick ascending limb of Henle is uncoupled
from its G protein/effector complex,5–10 a state that is asso-
ciated with increased basal phosphorylation of the D1R.
8,11
This finding is of interest because the functional status of
dopamine receptors is determined, in part, by their state
of phosphorylation, a process common to members of the
GPCR superfamily.12–14 Agonist occupation of GPCRs results
in generation of second messengers, receptor phosphory-
lation, and desensitization causing a decrease in GPCR
responsiveness to subsequent agonist stimulation.13–15 Upon
removal of the agonist, the attenuated responsiveness of
the receptor is reversed by a dephosphorylation process
subserved by protein phosphatases, probably of the 2A or 2B
type, in the case of D1-like receptors.
16–18 The depho-
sphorylation leads to cell surface membrane recycling and
resensitization of GPCRs.
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We have reported that the uncoupling of the D1R in renal
proximal tubules in the SHR may be a consequence of a
defective resensitization process, caused by decreased activity
of protein phosphatase2A (PP2A).
16 However, the phosphor-
ylation state and the cell surface membrane localization of the
D1R in kidneys of SHRs have not been reported. Therefore,
the current studies were designed to determine the phospho-
rylation state and subcellular distribution of D1 receptors
(D1Rs) in renal proximal tubules of WKY and SHRs. As
the D1R is phosphorylated at serine residues,
8,11,14,15,19,20 we
measured the amount of serine-phosphorylated D1Rs in renal
cortical and brush border membranes (BBMs), and im-
mortalized renal proximal tubule cells (RPTCs). In addition,
we determined whether increasing protein phosphatase
activity by pretreatment of cell membranes with the catalytic
subunit of alkaline phosphatase21,22 or increasing PP2A
activity in intact RPTCs, by protamine,12,23,24 can enhance
D1R function in SHRs.
RESULTS
Phosphorylation of D1Rs
To determine the extent of phosphorylation of the D1R, ex
vivo and in vitro studies were performed using freshly
obtained rat kidney cortices, freshly prepared BBMs, and
immortalized RPTCs because renal D1Rs are predominantly
located in proximal tubules.1,7–11,16,25–31 Moreover, the D1R
defect in spontaneous hypertension has been well character-
ized in renal proximal tubules.1–3,5,7–11,16,25–27,32 Basal levels of
serine-phosphorylated D1R were greater in renal cortical
membranes, BBMs, and immortalized RPTCs from SHRs
than from WKY rats (Figure 1, Table 1). The D1-like agonist,
fenoldopam, increased the quantity of serine-phosphorylated
D1R in WKY rats but not in SHRs (Figure 1, Table 1).
Pretreatment with carbidopa (renal cortical membranes and
BBMs) had no effect on basal serine phosphorylation of D1Rs
(not shown). Therefore, the results from the non-treated and
treated groups were pooled together.
Distribution of D1Rs in RPTCs
In order to determine the relative subcellular distribution of
D1Rs, we studied immortalized RPTCs in culture. Using live
cells labeled with a cell-impermeant and non-cleavable biotin
(sulfo-N-hydrosuccinamide (NHS)-biotin) reagent,25,32 we
found that the cell surface membrane fluorescence intensity
was greater in WKY than in SHRs (Figure 2a). The cell
surface membrane proteins (red) and D1Rs (green) showed
extensive colocalization (yellow) in cells from WKY rats, but
were markedly reduced in cells from SHRs. Indeed, most of
D1Rs were internal to the cell surface membranes in SHRs.
We also compared the fluorescence intensity in permea-
bilized and non-permeabilized cells.
The D1R can be visualized in non-permeabilized cells
because the polyclonal D1R antibody recognizes the third
extracellular loop of the receptor. In non-permeabilized
cells, fluorescence intensity was again greater in WKY than
in SHRs (Figure 2b). However, after cell permeabilization,
the total cellular expression of D1Rs was similar in WKY and
SHRs (Figure 2b), consistent with our previous report that
the expression of D1Rs, quantified by immunoblotting, in
renal cortex or in RPTCs was similar in WKY and SHRs.10
To verify the visual impression of decreased cell surface
membrane D1Rs in RPTCs from SHRs, cells were cultured in
Transwells to maintain apical and basolateral polarity.
Cell surface membrane proteins were biotinylated with
cell impermeant and non-cleavable sulfo-NHS-biotin,
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Figure 1 | Serine phosphorylation of D1Rs in membranes from rat
kidney cortex, brush border membranes (BBM) from rat kidney,
and immortalized RPTCs from WKY and SHRs. Membranes were
prepared as described in ‘Supplementary text’. Membrane
proteins were subjected to immunoprecipitation with monoclonal
anti-phosphoserine antibodies and immunoblotting with polyclonal
anti-D1R antibodies as described in ‘Materials and Methods’. The
immunoreactive bands (E70–80 kDa) were quantified by
densitometry. WC and SC, controls from WKY and SHR cells,
respectively; WF and SF, fenoldopam-treated cells from WKY and
SHRs, respectively. Results are expressed as mean7s.e.m., n¼ 4–5/
group, *Po0.05 vs other groups except for cells from SHRs
treated with D1-like agonist, ANOVA, Newman–Keuls test. Inset is
one of 4–5 independent immunoblots.
Table 1 | Serine-phosphorylated D1Rs in cortical and BBMs from kidneys and immortalized RPTCs from WKY and SHRs were
quantified by co-immunoprecipitation/immunoblotting as described in ‘Materials and Methods’
Kidney cortex BBM RPTC
WKY SHR WKY SHR WKY SHR
Control/vehicle 773* 2171.5 874* 3674 1471.9* 3172.2
Fenoldopam (5mM) 5573 1776 2574 3175 3872.1 2473.5
ANOVA Student—Newman–Keuls, *Po0.05, WKY control vs WKY fenoldopam-treated and SHR control, n=4–5.
The results in density units from Figure 1 are shown.
Abbreviations: BBMs, brush border membranes; D1Rs, D1 receptors; RPTC, renal proximal tubule cell.
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immunoprecipitated with anti-D1R antibodies, and immuno-
blotted with avidin-conjugated peroxidase (Figure 2c). D1R
abundance at the apical membranes was greater in cells
from WKY rats (67.874.4 density units, DU) than those
from SHRs (32.174.7 DU) (Figure 2c), corroborating the
immunofluorescence studies in Figure 2a and b. In contrast,
D1Rs were mainly located at basolateral membranes in cells
from SHRs (67.174.5 DU) relative to cells from WKY rats
(33.87.4.6 DU). Comparison of protein abundance in BBMs
between WKY and SHRs is not precise because proteins can
be redistributed within renal brush border microvilli33 and
D1Rs are present in both brush border and subapical
membranes.
We next studied the immunohistochemistry of rat kidney
sections. We found that the cellular distribution of D1Rs in
renal cortical tubules was different between WKY and SHRs.
In the renal cortex of WKY rats, D1Rs were mainly located at
microvillous brush border and apical membranes. In
contrast, in SHRs, D1Rs were distributed throughout the
cytosol with minimal expression at brush border and apical
membranes (Figure 3). Therefore, the kidney section studies
confirmed the results obtained in immortalized RPTCs
(Figure 2a, b and c). We also stained for rab GTPase 5
(Rab5), a marker protein for early or sorting endosome.
Rab5-positive endosomes have been shown to serve as sorting
compartments for both receptor recycling and degradation
pathways.34–36 Several studies have shown that internalized
GPCRs, such as the b2-adrenergic receptor, and the AT1R,
colocalize with Rab5 in endocytic vesicles.35,36 We found that
in the kidney cortex, Rab5 was distributed throughout the
cytosol in both rat strains. However, some Rab5 expression
was also observed in apical membranes in WKY. In contrast,
the colocalization of D1R with Rab5 in small vesicles (yellow
color) in SHRs was mainly located at the basal membranes
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Figure 2 | Distribution of D1Rs in immortalized RPTCs from WKY and SHRs. (a) Cellular distribution of D1Rs in live cells. Cellular distribution
was determined with cell-impermeant, non-clealvable biotin-labeling of live cells examined with double immunofluorescence confocal
microscopy, as described in ‘Materials and Methods’. Confocal images showed biotin-labeled membrane proteins as red color, and the D1R
as green color. The colocalization was seen as a yellow color in ‘merge’. The image is one of at least three separate experiments. Bar¼ 20mm.
(b) Cellular distribution of D1Rs by immunofluorescence. Non-permeabilized RPTCs from WKY rats had greater immunofluorescence than in
SHRs. After permeabilization, fluorescence intensities were similar in the two rat strains. (c) Quantitation of D1Rs on surface membranes of
RPTCs from WKY and SHRs. The quantity of D1Rs in apical and basolateral membranes was determined by biotinylation of proteins at the
surface membranes of RPTCs grown on Transwells, as described in ‘Materials and Methods’. D1R density at the apical membranes was greater in
WKY (67.874.4 DU) than in SHRs (32.174.7 DU). In contrast, D1R density was greater at the basolateral membranes in SHRs (67.174.5 DU) than
in WKY rats (33.87.4.6 DU) (Po0.01, ANOVA Newman–Keuls test, n¼ 5). Inset is one immunoblot.
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(Figure 3). The results indicated that more D1Rs colocalized
in Rab5-positive compartment vesicles in SHRs relative to
WKY rats under basal conditions.
Effect of protamine on cAMP accumulation and distribution
of D1Rs
In preliminary studies, we found that the D1R co-immuno-
precipitated with PP2A catalytic subunit (PP2Ac) but not with
PP1 or PP2B in both WKY and SHRs (data not shown). The
data indicated that PP2A may directly interact with D1R and
that PP2A may play a more important role than other
protein phosphatases in D1R regulation. PP2A has been
reported to be important in the dephosphorylation and
resensitization of the D1R.
16,17 Whereas, a D1R agonist
(fenoldopam) increased PP2A activity in renal proximal
tubules from WKY rats, PP2A activity was decreased by
fenoldopam in SHRs.16 We next determined the conse-
quences of protamine treatment on D1R-mediated increase
in cAMP accumulation and membrane expression of D1Rs.
Protamine has been shown to stimulate PP2A activity but
inhibit PP1 activity.
12,23,24 We found that pretreatment of
immortalized RPTCs with protamine overnight increased
PP2A activity by 7775.5% in WKY and 91.5711.8% in
SHRs. Basal (control) cAMP levels in immortalized RPTCs
were higher in WKY rats (282730 pmol/mg protein/20 min)
than in SHRs (123718 pmol/mg protein/20 min, n¼ 4-5/
group, Po0.05 t-test). Protamine increased fenoldopam-
induced cAMP accumulation in RPTCs from SHRs (1774%)
(Figure 4a) to the same degree observed in RPTCs from WKY
rats (2473%). These studies suggested that increasing PP2A
activity, and presumably the dephosphorylation of the D1R,
restored D1R responsiveness to agonist stimulation in SHRs
(see below).
Agonist-induced internalization of D1R has been reported
in many cell lines and types.15,37,38 In our studies in RPTCs
from WKY rats, fenoldopam stimulation resulted in more
D1R expression at the surface of one pole of the cell (observed
under non-permeabilized conditions). The areas that lacked
D1R on the cell surface of non-permeabilized cells were
probably the areas where the D1R got internalized (with
fenoldopam treatment) and therefore, could not be detected
by fluorescence microscopy under non-permeabilized condi-
tions. The D1Rs were internalized by 6474% in RPTCs from
WKY rats. In contrast, fenoldopam did not induce
internalization of D1Rs in RPTCs from SHRs (1.071.1%,
Po0.01, n¼ 3) (Figure 4b). However, protamine pretreat-
ment enabled fenoldopam to internalize more D1Rs on the
cell surface membranes of RPTCs from SHR (45.575.8%)
(Figure 4b), indicating that protamine allowed expression of
D1Rs on the cell surface that were then internalized with
fenoldopam stimulation. It is also possible that recruit-
ment of D1Rs at one cell surface pole was increased by
fenoldopam in WKY rats and that the recruitment was
improved by protamine treatment in SHRs. Fenoldopam has
been reported to increase the recruitment of D1Rs to cell
surface membranes of LLCPK1 cells.39
Effect of pretreatment of RPTC membranes with alkaline
phosphatase on the ability of D1-like receptor stimulation
of adenylyl cyclase activity
To confirm the results obtained with protamine, we
determined the effect of alkaline phosphatase treatment on
adenylyl cyclase activity in RPTC membranes from SHRs.
This method has been used to show the importance of
dephosphorylation on the ability of natriuretic peptide
receptor B to stimulate guanylyl cyclase activity.22 Basal
Rab5
DIC Merge DIC Merge
WKY SHR
D1R Rab5 D1R
Figure 3 | Colocalization of D1R with Rab5 in proximal tubules from rat kidney sections. Double immunofluorescence staining was
performed as described in ‘Materials and Methods’. The cellular distribution of D1Rs in renal cortical tubules was different between WKY and
SHRs. In WKY rats, D1Rs (red color) were mainly located at microvillous brush border and apical membranes. In contrast, in SHRs, D1Rs were
distributed throughout the cytosol with minimal expression at brush border and apical membranes. Rab5 (green color) was distributed
throughout the cytosol in both rat strains. However, some Rab5 expression was also observed in apical membranes in WKY. In contrast, in SHRs,
the colocalization of D1R with Rab5 in small vesicles (yellow color) was mainly located at the basal membranes. The image from transmitted
light (DIC, differential interference contrast) is shown in gray. The image is one of the three separate experiments. Bar¼ 20mm.
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adenylyl cyclase activity was similar in RPTCs from SHRs and
WKY (52.478.0 and 55.5718.9 pmol/mg/min). (Note: the
greater basal cAMP levels in intact RPTCs from WKY rats
than in SHRs may be due to the fact that receptor recycling
from the cytosol to the cell surface membranes could not
occur in membranes.) Fenoldopam (5 mmol/l/10 min) in-
creased adenylyl cyclase activity in RPTCs from WKY
(50710% from control), but not in RPTCs from SHRs
(1.072.5%), consistent with previous reports.10,16 A 20-min
pretreatment of RPTCs with alkaline phosphatase decreased
the basal adenylyl cyclase activity in membranes from RPTCs
from SHRs (15.272.3 pmol/mg/min, Po0.05, paired t-test,
n¼ 6). A purified catalytic subunit of PP2A has been reported
to decrease basal guanylyl cyclase activity.22 It is possible that
the decrease in basal adenylyl cyclase activity with alkaline
phosphatase treatment may reflect a change in intrinsic
activity of adenylyl cyclase (agonist independent activity).37
In spite of the decrease in basal adenylyl cyclase activity,
alkaline phosphatase treatment enhanced the ability of the
D1R agonist, fenoldopam, to stimulate adenylyl cyclase in
RPTC membranes from SHRs (2676%) (Figure 5a). Thus,
dephosphorylation of the hyperphosphorylated rat D1Rs in
RPTCs from SHRs (Figure 5b) restored the sensitivity of
D1Rs to agonist stimulation.
DISCUSSION
Desensitization of many GPCRs, defined as loss of respon-
siveness following agonist treatment, is thought to involve
largely their phosphorylation by a variety of protein
kinases, including G protein-coupled receptor kinase
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Figure 4 | Effect of protamine treatment on cAMP accumulation
and cellular distribution of D1Rs in immortalized RPTCs from
WKY and SHRs. (a) Cells were treated with vehicle (control) or the
D1-like agonist, fenoldopam, in the presence or absence of protamine
as described in ‘Supplementary text’. In RPTCs from SHRs not treated
with protamine, fenoldopam did not increase cAMP accumulation
(5.874.1% increase from control). After protamine treatment,
fenoldopam increased cAMP accumulation in RPTCs from SHRs
(þ 45713% to the same degree as those observed in RPTCs from
WKY rats (þ 64721.1%) (n¼ 4–5 group, *Po0.05 vs fenoldopam,
paired t-test). (b) Effect of protamine on the cellular distribution of
D1Rs in RPTCs from SHRs. The cells, grown on coverslips, were treated
with protamine as in (a), and immunofluorescence was studied under
non-permeabilized conditions. Fenoldopam (5 mmol/l/10 min) in-
creased D1R expression at one pole of WKY cells (6474%, top panel)
but not in SHR cells (1.071.1%, Po0.01, n¼ 3) (middle panel).
Protamine treatment of SHR cells enabled fenoldopam to increase
D1R expression at one pole of SHR cells (bottom panel) (45.575.8%).
The image is one of at least three separate experiments. Bar¼ 10 mm.
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Figure 5 | Effect of alkaline phosphatase (AP) treatment on
adenylyl cyclase activity and serine phosphorylation of D1Rs in
membranes of immortalized RPTCs from WKY and SHRs. (a) Effect
of alkaline phosphatase on adenylyl cyclase activity. Membrane
proteins from RPTCs were incubated with alkaline phosphatase as
described as in ‘Materials and Methods’. Fenoldopam (5 mmol/l/
10 min) did not increase adenylyl cyclase activity in RPTCs from SHRs.
Pretreatment of the membranes for 20 min with alkaline phosphatase
enabled fenoldopam to increase adenylyl cyclase activity in RPTCs
from SHRs (*Po0.05, vs fenoldopam, paired t-test, n¼ 6). (b) Effect of
AP on D1R phosphorylation in SHRs. Some of the RPTC membrane
proteins from SHRs (Figure 4a) were lysed in TBSN buffer (see
Materials and Methods) and subjected to immunoprecipitation with
anti-phosphoserine antibody as in Figure 1. Alkaline phosphatase
treatment decreased the basal phosphorylation of D1Rs and
increased the fenoldopam-induced phosphorylation of D1Rs (similar
to those noted in RPTCs from WKY rats – see Figure 1).
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(GRKs).1,11,13–15,19,29,38,40 Agonist stimulation phosphorylates
the D1R at serine and threonine but not tyrosine
residues.8,11,14,15,19,38,40,41 In renal tissue, the serine phos-
phorylation of the D1R is carried out by GRKs, mainly by
GRK4, with minor contribution by GRK2, and resulting in its
desensitization.8,11,29 We have also reported that D1R depho-
sphorylation, recycling to the cell surface membrane, and
resensitization is abnormal in SHRs because of impaired activity
of PP2A.
16 Therefore, it is possible that the increased phosphor-
ylation of the D1R in RPTCs from SHRs is caused both by
increased GRK activity and decreased PP2A activity. The aim of
this study was to determine the effect of dephosphorylation on
D1R subcellular localization and function in RPTCs from SHRs.
The quantity of phosphorylated D1R in the basal state is
greater in BBMs and renal cortex membrane, as well as in
membranes of immortalized RPTCs, from SHRs than from
WKY rats (Figure 1). This finding is in agreement with our
studies in primary cultures of RPTCs from humans
with essential hypertension compared with normotensive
humans.8,11 The similarity of the findings in the native
kidney, primary culture of RPTCs in humans, and immo-
rtalized RPTCs in rats indicates that immortalization
does not confer ‘spurious’ phenotypes, at least as far as the
D1R
5,7,9,10,16,25–27,29 and AT1R are concerned.
42
We now report that the cell surface membrane expression
(determined morphologically and biochemically) of D1Rs is
decreased in immortalized RPTCs from SHRs relative to
WKY rats (Figure 2c), in spite of similar quantities of D1Rs in
whole cells.10 In the kidney of WKY rats, the D1Rs are
mainly located at the microvillous brush border and apical
membranes, but less at the apical membranes in SHRs,
consistent with the studies in immortalized RPTCs (Figure
2c). The increased colocalization of D1R with Rab5 (Figure 3)
in SHRs may reflect internalized D1Rs that could not be
recycled back to the apical membranes because of hyperp-
hosphorylation of these receptors. The serine hyperpho-
sphorylation of D1Rs in SHRs accompanied by a decrease in
expression at cell surface membranes, and an increase in
colocalization with Rab5 may be taken to indicate that a
majority of D1Rs in renal proximal tubules are internalized
and failed to be recycled to the cell surface membrane,
resulting in defective function.1,3,5–11,16 A similar process may
explain the impaired renal D1R function and high blood
pressure associated with aging.20
We utilized pharmacological and biochemical approaches
to determine whether the D1R dysfunction in immortalized
RPTCs of SHRs can be ameliorated. Protamine inhibits PP1
activity but stimulates PP2A activity by targeting the PP2A-A
subunit to interact with the PP2A catalytic subunit.
12,23,24 A
concentration of protamine that has been documented to
increase PP2A and decrease PP1 activity increases D1R density
on cell surface membranes and responsiveness of D1R to
agonist stimulation in SHRs (Figure 3a and b). The
protamine-induced change in D1R expression may be the
consequence of the resensitization of D1Rs recruited from
internalized receptors to a polar side of the cell surface.
Fenoldopam, the D1-like agonist used in our studies, has
been reported to increase the recruitment of D1Rs to the cell
surface membrane of porcine renal cells, increasing D1R
responsiveness.39
To examine further the role of increased protein
phosphorylation on D1R dysfunction in SHRs, membranes
from immortalized RPTCs were treated with alkaline
phosphatase. Alkaline phosphatase has been used to study
the role of dephosphorylation in GPCR function.21 In the
current studies, to measure adenylyl cyclase activity, mem-
branes rather than intact cells were used. While increasing
PP2A activity with protamine in intact cells does not alter
basal cAMP levels, basal adenylyl cyclase activity is decreased
by the alkaline phosphatase treatment of RPTC membranes
from SHRs. Nevertheless, alkaline phosphatase treatment of
membranes from immortalized RPTCs from SHRs decreases
the quantity of serine-phosphorylated D1R (Figure 4b) and
enhances the ability of a D1R agonist to stimulate adenylyl
cyclase activity (Figure 4a), in agreement with the results of
the protamine studies. Taken together with the data using
intact cells and protamine, these data strongly support the
hypothesis that the hyperphosphorylation of the D1R is
responsible for the decreased D1R activity in the SHR.
In summary, we have found increased basal levels of
serine-phosphorylated D1R in renal cortical membranes
and BBMs and RPTCs from SHRs. This was associated
with decreased levels of cell surface membrane D1Rs (in
SHRs), in spite of similar expression of D1Rs in the whole
RPTCs in WKY and SHRs. Increasing protein phosphatase
activity, specifically PP2A, increased D1Rs on the cell surface
membrane, enabled a D1-like agonist to alter D1R cell
surface expression, and normalized D1R linkage to adenylyl
cyclase in the SHR. The cause of the impaired PP2A action
in SHRs is not known; however, we have reported that
the regulatory PP2A subunit, B56a, is not properly targeted
to the renal proximal tubular cell membrane in SHR.16
The cause of the mis-targeting of PP2A B56a remains to
be determined.
MATERIALS AND METHODS
Immunoprecipitation and immunoblotting
Immunoprecipitation of serine-phosphorylated D1Rs. Mem-
branes from kidney cortex, BBMs, and RPTCs (0.5–1 mg protein)
were incubated with 4 mg anti-phosphoserine antibodies and
protein G beads with rocking for 2 h or overnight in a cold room.
The immune complexes on the beads were washed with homo-
genizing buffer, eluted with Laemmli buffer, and boiled for 10 min.
The immunoprecipitates were then immunoblotted with polyclonal
affinity-purified rabbit anti-rat D1R antibody. The amount of
protein transferred onto the nitrocellulose membrane was verified
by Ponceau-S stain. All blots were visualized by ECL and quantified
by densitometry, using Quantiscan, as reported.10,16,25–27,29 All the
data from different runs were normalized so that the sum of all
density units from each run was 100%.
Biotinylation of apical and basolateral membrane proteins. The
cells, cultured in Transwells, were washed with Dulbecco’s modified
Eagle’s medium /F12-serum-free medium (SFM). Cell surface
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membrane proteins were biotinylated25,32 by adding a non-cleavable
cell-impermeant biotin reagent (EZ-link sulfo-NHS-biotin) dis-
solved in SFM (500 mg/ml) to either the apical side (upper chamber)
or basal side (lower chamber). The cells were incubated for 20 min
on ice, washed, and lysed in phosphate-buffered saline containing
1% NP-40, 0.1% sodium dodecyl sulfate, 0.5% deoxycholate, and
centrifuged 16 000 g for 10 min. The supernatants were subjected to
immunoprecipitation with anti-D1R antibody and immunoblotting
with avidin-conjugated peroxidase.
Enzymatic dephosphorylation and adenylyl cyclase assay
For the dephosphorylation experiment and adenylyl cyclase assay,
immortalized RPTCs from WKY and SHRs were used. The
membranes were freshly prepared as described previously.10,16,25
The membranes were resuspended in Tris and EDTA (TE) buffer
containing 2 mM MgCl2 (TEM buffer),
25 and subjected to enzymatic
treatment with alkaline phosphatase.21,22 The membranes (40 mg)
were incubated with 5–10 units of alkaline phosphatase in 50 ml of
reaction buffer (with the alkaline phosphatase kit) at room
temperature for 20 min. Okadaic acid, a serine/threonine phospha-
tase inhibitor, was added (0.1 mmol/l) to stop the reaction. The
membranes were assayed for adenylyl cyclase activity according to
our published protocol.28 Protein concentrations were determined
using a protein assay kit.
Immunofluorescence microscopy
RPTC immunofluorescence staining was performed according to
our previous report.25 Briefly, RPTCs were grown on glass cover
slips, fixed with 2% formaldehyde for 10 min at room temperature,
and washed three times with phosphate-buffered saline. The cells
were then stained under non-permeabilizing or permeabilizing
conditions. Permeabilization was achieved by incubation with 0.1%
Triton X-100 in phosphate-buffered saline buffer, for 10 min at
room temperature. Some cells were pretreated with vehicle or
protamine (5mmol/l) (to increase PP2A activity)
12,23,24 in complete
culture medium for 24 h prior to treatment with fenoldopam.
The cells were incubated anti-D1R antibody (1:200) followed by
Alexa 488-conjugated goat anti-rabbit secondary antibody (1:500).
After extensive washing, the cover slips were mounted and the
fluorescence densities and images were obtained using laser confocal
scanning microscopy (Olympus Fluoview FV600) with original
magnification  60 objective at an excitation wavelength of 488 nm;
emission was detected at 505 nm. A total of 15 images from each
cover slip (n¼ 3) were counted for quantitation of receptor
internalization.43
Immunohistochemical staining of rat kidney tissue
Rat kidney sections were prepared as described previously.44 Briefly,
the rat kidney was pre-flushed with an isotonic phosphate buffer
and fixed with 2% glutaraldehyde through the aorta at a pressure of
140 mm Hg, and subsequently embedded in paraffin. Kidney
sections were deparaffinized, rehydrated, permeabilized, and
blocked with 5% goat serum. For D1R colocalization with Rab5,
the kidney sections were double-stained with specific polyclonal
rabbit anti-rat D1R and monoclonal anti-Rab5 antibodies, followed
by Alexa 568-conjugated goat anti-rabbit and Alexa 488-conjugated
goat anti-mouse secondary antibodies (1:500). The secondary
antibodies also served as negative controls; no staining was observed
using only the secondary antibodies (data not shown). The
fluorescence images were obtained by laser scanning confocal
microscopy, as described.25
Live cell labeling for confocal imaging
Cell surface membranes of live RPTCs grown on coverslips were
labeled with EZ-link sulfo-NHS-biotin.21,25,32 Live cells were
washed once with Dulbecco’s modified Eagle’s medium/F12 SFM
and biotin-labeled (500mg/ml in SFM) for 20 min on ice.25 The
cells were washed three times with cold phosphate-buffered
saline containing glycine (10 mmol/l), pH 7.0. The cells were then
incubated for 10 min with avidin-conjugated CyTM 5 (far red) (1:100
dilution in SFM) on ice. The cells were fixed and subjected to dual
immunofluorescence staining with an anti-rat D1R antibodies
conjugated with Alexa-488. Cover slips were washed, mounted,
and subjected to confocal microscopic study as above. For CyTM5, the
excitation wavelength was 650 nm; emission was detected at 670 nm.
Statistical analyses
The data are expressed as means7s.e. Comparison within groups
was made using analysis of variance (ANOVA) for repeated
measures (or paired t-test when only two groups were compared)
and comparison among groups was made using factorial ANOVA
with Neuman–Keuls test (or t-test when only two groups were
compared). Corresponding periods between two different groups
were analyzed using independent t-test. Po0.05 was considered
significant.
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